Point72 Asset Management
KYTX icon

Point72 Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

Point72 Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-222,929
Closed -$1.92M – 4672
2026
Q1 		$1.92M Buy
222,929
+190,745
+593% +$1.59M ﹤0.01% 2327
2025
Q4 		$303K Buy
32,184
+5,008
+18% +$37.2K ﹤0.01% 3468
2025
Q3 		$163K Sell
27,176
-28,346
-51% -$113K ﹤0.01% 2159
2025
Q2 		$170K Buy
+55,522
New +$137K ﹤0.01% 2010
2024
Q4 		– Sell
-34,482
Closed -$169K – 2524
2024
Q3 		$169K Buy
+34,482
New +$266K ﹤0.01% 1820
2024
Q2 		– Sell
-20,900
Closed -$519K – 2546
2024
Q1 		$519K Buy
+20,900
New +$583K ﹤0.01% 1638

Other funds holding KYTX

GordonMD Global Investments
GordonMD Global Investments Beverely Hills, California $207M AUM
Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Insight Holdings Group
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Point72 Asset Management's KYTX Position: Q2 2026 in Review

Point72 Asset Management sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 222,929 shares — an estimated $1.92M sold.

Point72 Asset Management first reported a position in KYTX in Q1 2024 and held it in 6 quarters. The position peaked at $1.92M in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Point72 Asset Management reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 222,929 Kyverna Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Point72 Asset Management first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 6 quarters.
  • Point72 Asset Management's Kyverna Therapeutics position peaked at $1.92M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.